Effects of Interleukin-4 or Interleukin-10 gene therapy on trinitrobenzenesulfonic acid-induced murine colitis by Jing Xiong et al.
Xiong et al. BMC Gastroenterology 2013, 13:165
http://www.biomedcentral.com/1471-230X/13/165RESEARCH ARTICLE Open AccessEffects of Interleukin-4 or Interleukin-10 gene
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Background: Inflammatory bowel disease (IBD) is characterized by disturbance of pro-inflammatory cytokines and
anti-inflammatory cytokines. Previous studies have demonstrated the effect of anti-inflammatory cytokines, such as
interleukin-10 (IL-10) or IL-4 on IBD, but their data were controversial. This study further investigated the effect of
IL-4 (IL-4), IL-10 and their combination on treatment of trinitrobenzenesulfonic acid (TNBS)-induced murine colitis.
Methods: pcDNA3.0 carrying murine IL-4 or IL-10 cDNA was encapsulated with LipofectAMINE 2000 and intraperitoneally
injected into mice with TNBS-induced colitis. The levels of intestinal IL-4 and IL-10 mRNA were confirmed by
quantitative-RT-PCR. Inflamed tissues were assessed by histology and expression of interferon (IFN)-γ, tumor necrosis
factor (TNF)-α and IL-6.
Results: The data confirmed that IL-4 or IL-10 over-expression was successfully induced in murine colon tissues after
intraperitoneal injection. Injections of IL-4 or IL-10 significantly inhibited TNBS-induced colon tissue damage, disease
activity index (DAI) and body weight loss compared to the control mice. Furthermore, expression of IFN-γ, TNF-α and
IL-6 was markedly blocked by injections of IL-4 or IL-10 plasmid. However, there was less therapeutic effect in mice
injected with the combination of IL-4 and IL-10.
Conclusions: These data suggest that intraperitoneal injection of IL-4 or IL-10 plasmid was a potential strategy in control
of TNBS-induced murine colitis, but their combination had less effect.
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Inflammatory bowel disease (IBD), including Crohn’s dis-
ease (CD) and ulcerative colitis (UC), is characterized by
chronic and relapsing inflammation of the gastrointestinal
tract that ultimately leads to the destruction of the intes-
tinal tissues. Epidemiologically, IBD affects approximately
1.4 million patients in the United States and 2.2 million
people in Europe [1]. Those with IBD have a high-risk of
developing colorectal cancer or toxic mega colon in the
clinic [2-4] and IBD severity, such as pan-colitis and those
with a disease course longer than 10 years have a higher
risk in developing colorectal cancer [5,6]. To date, the pre-
cise etiology of IBD has not been elucidated, but it is now* Correspondence: baiyang1030@hotmail.com; liuside@163.com
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reproduction in any medium, provided the orwidely accepted that an inadequate activation of CD4+ T
helper 1, Th 2 and Th 17 immune cells cause an imbalance
between pro-inflammatory and anti-inflammatory cyto-
kines, which plays a crucial role in IBD pathogenesis [7,8].
Specifically, IL-10 plays a pivotal role in the mucosal
immune system by inhibition of pro-inflammatory cyto-
kine synthesis and antigen presentation and in turn alle-
viates intestinal inflammation [9-11]. IL-10 knockout
mice spontaneously developed chronic enterocolitis re-
sembling human CD [12]. Local delivery of plasmid car-
rying IL-10 cDNA ameliorated intestinal inflammation
in a chemical acute colitis animal model [13-15]. More-
over, IL-4, as an anti-inflammatory cytokine, is less well
elucidated in IBD. It possesses immunoregulatory and im-
munosuppressive effects in the gut through mediating the
differentiation of naive T cells to Th2 cell and inducing
Th2-type CD4+ T cells to shift towards a Th1 responsetd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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in IBD [20]. The efficacy of IL-4 treatment in murine IBD
models is contentious [21].
In this study, we investigated the effects of IL-4 or/and
IL-10 gene therapy on TNBS-induced murine colitis. We
injected intraperitoneally plasmids carrying IL-4 or/and
IL-10 cDNA into mice with TNBS-induced murine colitis
and tested the effects of transgenic expression on TNBS-
induced murine colitis. We also measured the colon tissue
levels of IFN-γ, TNF-α and IL-6. Taken together, evalu-
ation of the protective effect of IL-4 on IBD might shed
light on alternative gene therapy of IBD.Methods
Plasmids
The recombinant plasmids, pcDNA3.0-mIL-4 and
pcDNA3.0-mIL-10, were constructed in our laboratory.
Briefly, murine IL-4 or murine IL-10 gene was obtained
by RT-PCR, was then integrated into the respective
eukaryotic expression plasmid pcDNA3.0, and the recom-
binant plasmid was finally confirmed by DNA sequencing.Mice and TNBS-induced colitis
In this study, animal protocols were approved by the
Institutional Animal Care and Use Committees of
Southern Medical University. Specifically, male BALB/
c mice (6–8 weeks of age with a body weight of 18–
22 g) were group-housed at our animal care facility
under a controlled temperature (25°C) and light–dark
cycle (12:12 h). The animals were allowed unrestricted
access to food and tap water. To induce the murine
colitis, we followed the procedures described by Wirtz
S et al. [22]. Briefly, the mice were first pre-sensitized
by using 1.5 mg TNBS (Sigma-Aldrich, St. Louis, MO)
applied to the skin. After 7 days, the mice were lightly
anesthetized by intraperitoneal injection of pentobar-
bital sodium salt and then rectally administered 2.5 mg
of TNBS dissolved in 100 μl of 50% (v/v) ethanol solu-
tion using a 1.5 mm polyethylene catheter. Mice were
then kept in a vertical position for 1 min. Control mice
were administered 50% ethanol in a similar manner
(n = 10 mice in each group).Table 1 Animal experiments






6 10 TNBSGene transfection of TNBS-treated mice
To assess the effect of pcDNA3.0-IL-4 or pcDNA3.0-IL-
10 on TNBS-induced colitis, we intraperitoneally in-
jected these plasmids into mice mixed with liposome
24 h after TNBS injection (Table 1) according to previ-
ous studies [23-30]. In brief, 100 μg plasmids were
mixed with 30 μl LipofectAMINE 2000 and then incu-
bated for 20 min at the room temperature, and injected
into mice. After that, daily weight, stool consistency,
rectal bleeding and animal behavior were recorded for
up to 7 days. Mice were sacrificed on day 7 and the
murine colon was removed for analyses of histology,
INF-γ, TNF-α and IL-6 levels.Evaluation of TNBS-treated mice
Body weight, stool consistency and gross bleeding were
monitored daily as described by Ganta et al. [31]. Disease
activity index (DAI) was determined by combined scores
of body weight loss, stool consistency and gross bleeding.
The scores were defined as follows: change in body weight
(0: none, 1: 1-5%, 2: 5-10%, 3: 10-15%, 4: >15%), stool
consistency (0: normal, 2: loose stool, 4: diarrhea) and
stool blood (0: negative, 2: positive, 4: gross bleeding).
Body weight loss was calculated as the percent difference
between the original body weight (day 0) and the body
weight on any given day.Histological analysis of colitis
At the end of experimenting, the distal colon was re-
moved from the mice and fixed in 4% paraformaldehyde,
embedded in paraffin, sectioned at 5 μm, and stained
with hematoxylin and eosin (HE). Histology of murine
colon tissues was independently evaluated by two expe-
rienced pathologists in a blinded fashion. Histological
changes were graded from 0 to 4: 0, no sign of inflam-
mation; 1, very low level of leukocyte infiltration; 2, low
level of leukocyte infiltration; 3, high level of leukocyte
infiltration, high vascular density and thickening of the
colon wall; and 4, transmural infiltration, loss of goblet
cells, high vascular density and thickening of the colon
wall according to a previous study [32].Treatment
30 μl LipofectAMINE
30 μl LipofectAMINE
100 μg pcDNA3.0 + 30 μl LipofectAMINE
100 μg pcDNA3.0-mIL-4 + 30 μl LipofectAMINE
100 μg pcDNA3.0-mIL-10 + 30 μl LipofectAMINE
50 μg pcDNA3.0-mIL-4 + 50 μg pcDNA3.0-mIL-10 + 30 μl LipofectAMINE
Figure 1 Quantitative RT-PCR detection of IL-4 and IL-10
expression in vivo. Colon tissue samples were removed from
TNBS-treated murine colitis on day 7 and subjected to RNA isolation
and qRT-PCR. A: The expression of IL-4 mRNA in vivo. B: The level of
IL-10 mRNA in vivo. The transgenic expression of IL-4 or IL-10 was
successfully induced. All data are expressed as mean ± s.d.
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Total cellular RNA was isolated from 50 mg colon tissue
using a Trizol Reagent (Invitrogen) according to the
manufacturer’s instruction and then reverse-transcribed
into cDNA using the M-MLV reverse transcriptase (Invi-
trogen) following the manufacturer’s instructions.
For qPCR, 2 μl of reverse transcription mixture was sub-
jected to PCR amplification of IL-4, IL-10, TNF-α, IL-6 and
β-actin mRNA using SYBR Green (TaKaRa, Tokyo, Japan)
in the LightCyler 480 instrument (Roche Diagnostics
Corporation, Indiana, USA) for 40 cycles. PCR primers
were as follows: IL-4, 5′-GGTCTCAACCCCCAGCTAGT





and 5′-AGTGCATCATCGTTGTTCATACAA-3′; and β-
actin, 5′-GATGACCCAGATCATGTTT-3′ and 5′-ACGA
CCAGAGGCATACAG-3′. The PCR amplification was in
duplicate. The differences in target gene expression were
expressed relatively to the housekeeping gene as 2ΔΔCT,
where ΔΔCT = average of ΔCTcontrol – ΔCT treated.
ELISA measurement of IFN-γ levels
To detect IFN-γ levels in murine colon tissues, we re-
sected approximately 30 mg colon tissues from control
and experimental mice which we homogenized in 150 μl
NP-40 lysis buffer and centrifuged at 14, 000 g for 30 min.
The supernatants were collected and assayed for IFN-γ
protein levels by using an ELISA kit (Raybio, Bruges,
Belgium) according to the manufacturer’s instructions.
Statistical analyses
The data were represented as mean ± standard deviation
(SD) and analyzed using one-way ANOVA. Repeated
measure ANOVA test was used to analyze the differences
in the DAI score and body weight changes between the
groups. The nonparametric data (such as HE scores or
levels of IFN-γ were analyzed by the Kruskal-Wallis test.
All statistical analyses were performed by using SPSS 13.0
software (SPSS, Chicago, IL). P < 0.05 was considered sta-
tistically significant.
Results
Detection of IL-4 and IL-10 transgene expression in vivo
To assess the effects of IL-4 or/and IL-10 expression on
treatment of TNBS-induced murine colitis, we intraperi-
toneally injected these plasmids into mice and then de-
tected these transgenic expressions in murine colon
tissues using qRT-PCR (Figure 1). In brief, the level of
IL-4 mRNA in the mice injected with IL-4 plasmid and
in the combination group was significantly higher than
that of pcDNA3.0 injection and TNBS-induced mice.Similarly, the level of IL-10 mRNA was also significantly
higher in the mice injected with IL-10 plasmid and the
combination group than pcDNA3.0 injection and TNBS-
induced mice. These data demonstrated that intraperito-
neal injection of these plasmids was able to induce the
transgenic expression in murine colon tissues.
Effects of IL-4 and IL-10 on treatment of TNBS-induced
microscopic injury of colon tissues
In the TNBS-induced colitis model, we found that TNBS
induced the colon tissues to severe inflammation, e.g.
thickening of the colon wall and a high level of leukocyte
infiltration (Figure 2A). In contrast, IL-4 and IL-10 trans-
genic expression prevented colitis histology, i.e., histology
of IL-4, IL-10 or their combination-treated colon tissues
appeared almost normal, with a low level of infiltrating
leukocytes (Figure 2A). Figure 2B summarized the median
histological score and showed that TNBS-treated mice
had prominently higher histological scores than that of all
other groups. Mice treated with IL-4, IL-10 or their com-
bination had significantly lower histological scores than
Figure 2 Effects of IL-4 or IL-10 transfection on treatment of
TNBS-induced murine colitis. IL-4 or IL-10 treatment attenuated
colonic inflammation and reduced histological colitis scores in TNBS-
induced murine colitis. In contrast, their combination has minimal ef-
fect on preventing colitis development. A: Hematoxylin and eosin
staining of the colon. Group 1, treated with TNBS only; Group 2,
treated with pcDNA3.0; Group 3, treated with IL-4; Group 4, treated
with IL-10; Group 5, treated with combination. Magnification, ×200.
Scale bar = 100 μm. B: Histologic scores of the colon tissues. Each tis-
sue section was evaluated for an inflammatory score from 0 to 4
and the data are expressed as median (*p < 0.05 compared to the
TNBS-only group using Kruskal Wallis test).
Figure 3 Effects of IL-4 or IL-10 on treatment of TNBS-induced
mouse body weight and disease severity. A: Disease activity
index. B: Body weight changes. All data are expressed as mean ± s.d.
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obvious difference in the histological scores among mice
administrated with combination pcDNA3.0 plus TNBS.
These data showed that a single injection of IL-4 or IL-10
was sufficient to ameliorate colitis.
Effects of IL-4 or IL-10 on treatment of TNBS-induced
murine body weight and disease severity
The changed body weight of each mouse was measured
every day by comparing the current weight with the weighton day 0 and the disease activity was also monitored
(Figure 3A). Compared with mice treated with IL-4 or IL-
10 after TNBS induction, the body weight of mice treated
with the combination treatment decreased significantly.
Compared with the control mice, the body weight of mice
administered with IL-4 or IL-10 had significant recovery in
day 3. Figure 3B showed the data of disease activity index,
i.e., the disease activity score of IL-4 or IL-10 mice nearly
returned back to normal on day 7, whereas the combin-
ation group maintained a high level, similar to TNBS only-
treated mice. These data indicate that administration of IL-
4 or IL-10 significantly attenuated body weight loss and
disease severity after TNBS-induced colitis, whereas the
combination treatment had no significant effect on this
process.
Effects of IL-4 or IL-10 on suppression of TNBS-induced
IFN-γ levels in TNBS-induced murine colitis
The acute colitis induced by TNBS administration is as-
sociated with the release of pro-inflammatory cytokines.
In order to determine the effect of IL-4 or IL-10 therapy
on TNBS-induced murine colitis, colonic levels of IFN-γ
Figure 5 Effects of IL-4 or IL-10 on suppression of TNBS-induced
TNF-α and IL-6 expression in TNBS-induced murine colitis. Mice
with TNBS-induced colitis showed a higher level of pro-inflammatory
cytokines (TNF-α and IL-6) than that of the mice treated with IL-4,
IL-10 and their combination. A: The colonic TNF-α expression was
determined by quantitative real-time RT-PCR. B: The expression
of colonic IL-6 in mice. The data are expressed as mean ± s.d.
(*p < 0.05 vs. the Control using one-way ANOVA with Dunnett's T3 test).
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and the results showed that TNBS-treated mice had ele-
vated levels of IFN-γ (1043.804 pg/ml), whereas IL-4 or
IL-10 therapy significantly reduced levels of IFN-γ pro-
tein (593.116 pg/ml and 421.204 pg/ml, respectively). In
contrast, the combination therapy has lower effects
(898.469 pg/ml vs. 593.116 pg/ml or 421.204 pg/ml, re-
spectively) (Figure 4).
Effects of IL-4 or IL-10 on suppression of TNBS-induced
TNF-α and IL-6 expression in TNBS-induced murine colitis
To further confirm the therapeutic effect of IL-4 and IL-
10 gene therapy, we performed qRT-PCR analysis of
their expression in TNBS-induced murine colitis tissues.
We found that TNBS treatment alone induced expres-
sion of TNF-α and IL-6 mRNA in the colon tissues,
whereas administration of IL-4, IL-10 or their combin-
ation significantly down-regulated expression of mucosal
TNF-α and IL-6 mRNA in the colon tissues (Figure 5).
Discussion
A number of animal models of intestinal inflammation, in-
dispensable for our understanding of the pathogenesis of
IBD and testing of novel therapeutics, have been estab-
lished by using chemical induction, immune cell transfer
or genetic manipulations [33]. A frequently used murine
model is based on the intrarectal administration of TNBS
and produced human-like CD and is characterized by
Th1-mediated inflammation [34]. Our current data con-
firmed this TNBS-induced colitis model with elevated
Th1-like cytokines. We also showed that IL-4 or IL-10
gene therapy had a markedly lower disease severity than
that of the TNBS alone-treated group. The body weight of
the treated mice was drastically recovered from day 4 to
day 7 and the levels of IFN-γ protein, TNF-α and IL-6Figure 4 Effects of IL-4 or IL-10 on suppression of TNBS-induced
IFN-γ levels in TNBS-induced murine colitis. Colonic IFN-γ levels
were measured by using ELISA and the data are expressed as
median (*p < 0.05 compared to the TNBS-only group using Kruskal
Wallis test).mRNA were remarkably down-regulated after IL-4 or
IL-10 gene therapy compared to TNBS alone-treated
mice. It is very interesting for us to find that the com-
bination of both cytokines had less effects that that of
each individual one.
Our current study is consistent with previous reports
on the role of IL-10 in intestinal inflammation [13-15].
Moreover, Barbara et al. showed that adenovirus carry-
ing IL-10 suppressed experimental colitis in rat [35].
Lindsay and his colleagues also showed that local IL-10
gene therapy using an adenoviral vector reversed colitis
in IL-10−/− mice after intravenous administration [36].
Moreover, our current data also confirmed the effects of
IL-4 on experiment colitis. This finding is consistent
with the data shown by Hogabaom et al. [37]. In fact,
despite the accumulated knowledge from experimental
IBD models, the biology of IL-4 in vivo remains contro-
versial. For example, IL-4 was shown to be either benefi-
cial or detrimental in different experimental settings.
Hogabaom et al. demonstrated that IL-4 delivered by
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rat colitis, which was associated with an inhibition of indu-
cible nitric oxide expression and a reduction in nitric oxide
synthesis. However, the acute DSS-induced colitis was exac-
erbated in IL4+/+mice, and not in IL4−/− mice [21]. Ac-
cordingly, Madeline et al. revealed that IL-4 indirectly
promoted Th1-type inflammation in the CD4+CD45RBhigh
T cell transfer model of colitis, while co-treatment with IL-
10 blocked the development of colitis [38]. Possible expla-
nations for the discrepancy may be because of variances in
animal models used (induction of disease, chemical versus
T cells or animals, rats versus mice), method of IL-4 admin-
istration (adenovirus versus liposome mediated plasmid de-
livery, time of cytokine addition (pre versus post). In
addition, the site of injection, administrated dosage, and mi-
lieu of cytokines may also be factors in affecting biological
activity of exogenous IL-4 in these IBD models.
In our current study, the mechanisms responsible for
IL-4 or IL-10 anti-colitis could be due to control of pro-
inflammatory cytokine production and immune cells ac-
cumulation in gut tissues. TNF-α and IFN-γ are master
cytokines in the pathogenesis of IBD. TNF-α can increase
IL-1β, IL-6 and IL-33 production as well as modulate ST2
expression in epithelial cells [39,40]. The serum levels of
TNF-α and sIL-6R were significantly increased in patients
with active UC and CD and correlate with the clinical ac-
tivity of UC and CD [41,42]. IL-6 signaling via signal
transducer and activator of transcription-3 (STAT3) plays
an important role in UC pathogenesis [43]. On the other
hand, recent studies also verified an important role for IL-
6 in the suppression of Treg function and in the develop-
ment of pathogenic Th17 cells, which are also involved in
IBD models [7,44].
There may be three potential explanations why the
combination treatment has less effect as a therapeutic
strategy, i.e., i) The administered dose of the combination
(half of each single dose) may not reach the effective dose
to elicit a protective response; ii) Their combination may
not be at their optimal concentrations for producing cli-
nical effects; and iii) Their immune-stimulatory effects
counterbalance their immune-suppressive properties. Co-
treatment with IL-10, IL-4 may exert pro-inflammatory
actions through synergizing with TNF-α to induce adher-
ence of eosinophil and basophil to endothelium, and
synergizing with IFN-γ to increase secretory component
expression by epithelial cells [45-47]. Thus, this study is
just a proof-of-principle and we did not determine how
IL-4 or IL-10 exerts its effect in the current animal model
and which cell types are responsible for mediating these
complex cell/cytokine interactions. Future work will
utilize these plasmids to test the effects of IL-4 and IL-
10 in other chronic murine inflammatory bowel disease
models. We will also explore the biological significance
of these cytokines in human IBD.Conclusions
In the current study, we investigated the effects of IL-4
or/and IL-10 gene therapy against TNBS-induced mur-
ine colitis and found that the liposome-mediated com-
bination gene therapy had a significant efficacy in
treatment of TNBS-induced murine colitis. Specifically,
treatment of mice with IL-4 or IL-10 resulted in a
marked improvement in the histological appearance of
the distal colon and suppression of Th1-cell type cyto-
kines, such as IFN-γ, TNF-α and IL-6 in TNBS-induced
murine colitis. However, treatment with combination cy-
tokines did not yield a similar effect as individual treat-
ment. The intraperitoneal injection of cytokine plasmid
plus liposome was well tolerated in the mice. Liposome
did not induce an acute phase response nor exacerbate
intestinal inflammation in control mice. Thus, the
current gene delivery method may be useful as a poten-
tial treatment modality. Future study will determine
their long-term effects in animal experiments before ap-
plying this method to human study.
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